Costs of severely ill members and specialty medication use in a commercially insured population

Health Affairs

Volumn 27, Issue 3, 2008, Pages 824-834

  Willey, Vincent J ^a   Pollack, Michael F ^b   Lednar, Wayne M ^c   Yang, William N ^d   Kennedy, Charles ^e   Lawless, Grant ^f,g  

^a HEALTHCORE INC   (United States)

^b Health Economics and Outcomes Research   (United States)

^c DUPONT COMPANY   (United States)

^d The Coca Cola Company   (United States)

^e Health Information Technology   (United States)

^f AMGEN INC   (United States)

^g Wellpoint Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; COST BENEFIT ANALYSIS; CRITICALLY ILL PATIENT; DRUG COST; DRUG USE; HEALTH CARE COST; HEALTH CARE PLANNING; HEALTH INSURANCE; HUMAN; MEDICINE; OUTCOME ASSESSMENT;

DRUG COSTS; DRUG UTILIZATION; HEALTH CARE COSTS; HUMANS; INSURANCE COVERAGE; INSURANCE, HEALTH; INSURANCE, PHARMACEUTICAL SERVICES; SEVERITY OF ILLNESS INDEX; UNITED STATES;

EID: 44449142605     PISSN: 02782715     EISSN: 02782715     Source Type: Journal    
DOI: 10.1377/hlthaff.27.3.824     Document Type: Article

References (18)

1. P. Fishman et al., "Chronic Care Costs in Managed Care," Health Affairs 16, no. 3 (1997): 239-247;
2. R.I. Garis and K.C. Farmer, "Examining Costs of Chronic Conditions in a Medicaid Population," Managed Care 11, no. 8 (2002): 43-50;
3. C. Hoffman, D. Rice, and H.Y. Sung, "Persons with Chronic Conditions: Their Prevalence and Costs," Journal of the American Medical Association 276, no. 18 (1996): 1473-1479;
4. and W. Yu et al., "The Relationships among Age, Chronic Conditions, and Healthcare Costs," American Journal of Managed Care 10, no. 12 (2004): 909-916.
5. Fishman et al., "Chronic Care Costs in Managed Care";
6. and Yu et al., "The Relationships."
7. H.T. Tu, "Rising Health Costs, Medical Debt, and Chronic Conditions," Issue Brief no. 88 (Washington: Center for Studying Health System Change, 2004).
8. Henry J. Kaiser Family Foundation, "Illustrating the Potential Impacts of Adverse Selection on Health Insurance Costs in Consumer Choice Models," November 2006, http://kff.org/insurance/snapshot/chcm111006oth2. cfm (accessed 30 January 2008).
9. Bureau of Labor Statistics, "Measuring Price Change for Medical Care in the CPI," 1 March 2007, http://www.bls.gov/cpi/cpifact4.htm (accessed 13 September 2007).
10. The medical services costs associated with infusion of medications are typically a small percentage of the acquisition costs for biologics. For example, Wu and colleagues found that the annual drug administration cost for infliximab, a biologic medication infused in the outpatient setting for the treatment of rheumatoid arthritis, was $725 and represented 4 percent of the annual cost of the drug. E. Wu et al., "Cost of Care for Patients with Rheumatoid Arthritis Receiving TNF-Antagonist Therapy Using Claims Data," Current Medical Research and Opinion 23, no. 8 (2007): 1749-1759.
11. In addition, changes in payment methodologies to physicians for drugs administered in their offices have greatly decreased reimbursement for the drug product. This may affect patient care if physicians decide not to administer drugs in their offices and refer patients to outpatient infusion centers for treatment; research on the influence of these reimbursement changes on the quality of care is needed. D. Stern and D. Reissman, "Specialty Pharmacy Cost Management Strategies of Private Health Care Payers," Journal of Managed Care Pharmacy 12, no. 9 (2006): 736-744.
12. J. Hsu et al., "Unintended Consequences of Caps on Medicare Drug Benefits," New England Journal of Medicine 354, no. 22 (2006): 2349-2359.
13. D.P. Goldman, G.F. Joyce, and P. Karaca-Mandic, "Varying Pharmacy Benefits with Clinical Status: The Case of Cholesterol-Lowering Therapy," American Journal of Managed Care 12, no. 1 (2006): 21-28.
14. D.P. Goldman et al., "Benefit Design and Specialty Drug Use," Health Affairs 25, no. 5 (2006): 1319-1331.
15. Goldman et al., "Varying Pharmacy Benefits";
16. D.P. Goldman et al., "Pharmacy Benefits and the Use of Drugs by the Chronically Ill," Journal of the American Medical Association 291, no. 19 (2004): 2344-2350;
17. and C.W. Tseng et al., "Cost-Lowering Strategies Used by Medicare Beneficiaries Who Exceed Drug Benefit Caps and Have a Gap in Drug Coverage," Journal of the American Medical Association 292, no. 8 (2004): 952-960.
18. M.C. Sokol et al., "Impact of Medication Adherence on Hospitalization Risk and Healthcare Cost," Medical Care 43, no. 6 (2005): 521-530.